Literature DB >> 32072388

Development and validation of prognostic nomograms in patients with adrenocortical carcinoma: a population-based study.

Hao Zhang1,2, Yaser Naji1, Minbo Yan1, Wenfei Lian1, Maochun Xie1, Yingbo Dai3,4.   

Abstract

BACKGROUND: Predicting the prognosis of patients with adrenocortical carcinoma (ACC) is difficult, due to its unpredictable behavior. The aim of this study is to develop and validate a nomogram to predict survival outcomes in patients with ACC.
METHODS: Nomograms were established using the data collected from the Surveillance, Epidemiology, and End Results (SEER) database. Based on univariate and multivariate Cox regression analyses, we identified independent risk factors for overall survival (OS) and cancer-specific survival (CSS). Concordance indexes (c-indexes), the area under the receiver operating characteristics curve (AUC) and calibration curve were used to evaluate predictive performance of these models. The clinical use of nomogram was measured by decision curve analysis (DCA) and clinical impact curves.
RESULTS: A total of 855 eligible patients, randomly divided into training (n = 600) and validation cohorts (n = 255), were included in this study. Based on the independent predictors, the nomograms were established and demonstrated good discriminative abilities, with C-indexes for OS and CSS were 0.762 and 0.765 in training cohorts and 0.738 and 0.758 in validation cohorts, respectively. The AUC and calibration plots also demonstrated a good performance for both nomograms. DCA indicated that the two nomograms provide clinical net benefits.
CONCLUSION: We unveiled the prognostic factors of ACC and developed novel nomograms that predict OS and CSS more accurately and comprehensively, which can help clinicians improve individual treatment, making proper clinical decisions and adjusting follow-up management strategies.

Entities:  

Keywords:  Adrenocortical carcinoma; Decision curve analysis; End results; Epidemiology; Nomogram; Surveillance

Year:  2020        PMID: 32072388     DOI: 10.1007/s11255-020-02413-1

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  26 in total

1.  The Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.

Authors:  Kathleen A Cronin; Lynn A G Ries; Brenda K Edwards
Journal:  Cancer       Date:  2014-12-01       Impact factor: 6.860

2.  Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?

Authors:  Electron Kebebew; Emily Reiff; Quan-Yang Duh; Orlo H Clark; Alex McMillan
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

3.  [The relationship of forensic medicine to hunting and hunter. 2].

Authors:  F J Holzer
Journal:  Arch Kriminol       Date:  1974 Mar-Apr

4.  Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.

Authors:  P Icard; P Goudet; C Charpenay; B Andreassian; B Carnaille; Y Chapuis; P Cougard; J F Henry; C Proye
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

5.  X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization.

Authors:  Robert L Camp; Marisa Dolled-Filhart; David L Rimm
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

6.  External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma.

Authors:  Laurent Zini; Umberto Capitanio; Claudio Jeldres; Giovanni Lughezzani; Maxine Sun; Shahrokh F Shariat; Hendrik Isbarn; Philippe Arjane; Hugues Widmer; Paul Perrotte; Markus Graefen; Francesco Montorsi; Pierre I Karakiewicz
Journal:  BJU Int       Date:  2009-06-02       Impact factor: 5.588

Review 7.  Update in adrenocortical carcinoma.

Authors:  Martin Fassnacht; Matthias Kroiss; Bruno Allolio
Journal:  J Clin Endocrinol Metab       Date:  2013-09-30       Impact factor: 5.958

8.  Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration.

Authors:  Karel G M Moons; Douglas G Altman; Johannes B Reitsma; John P A Ioannidis; Petra Macaskill; Ewout W Steyerberg; Andrew J Vickers; David F Ransohoff; Gary S Collins
Journal:  Ann Intern Med       Date:  2015-01-06       Impact factor: 25.391

9.  The Characteristics and Trends in Adrenocortical Carcinoma: A United States Population Based Study.

Authors:  Eliza Sharma; Suyash Dahal; Pratibha Sharma; Abani Bhandari; Vishal Gupta; Birendra Amgai; Sumit Dahal
Journal:  J Clin Med Res       Date:  2018-06-27

10.  Nomograms to predict overall survival and cancer-specific survival in patients with adrenocortical carcinoma.

Authors:  Yan Li; Xiaohui Bian; Junyu Ouyang; Shuyi Wei; Meizhi He; Zelong Luo
Journal:  Cancer Manag Res       Date:  2018-12-13       Impact factor: 3.602

View more
  2 in total

1.  S-GRAS score performs better than a model from SEER for patients with adrenocortical carcinoma.

Authors:  Wenhao Lin; Jun Dai; Jialing Xie; Jiacheng Liu; Fukang Sun; Xin Huang; Wei He; Chen Fang; Juping Zhao; Danfeng Xu
Journal:  Endocr Connect       Date:  2022-06-21       Impact factor: 3.221

2.  Comparative performances of nomograms and conditional survival after resection of adrenocortical cancer.

Authors:  M C de Jong; S Khan; I Christakis; A Weaver; R Mihai
Journal:  BJS Open       Date:  2021-01-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.